Adaptive Biotechnologies (ADPT) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Adaptive Biotechnologies (ADPT) do?
Adaptive Biotechnologies Corp (ADPT) is a U.S.-listed company in Healthcare (Diagnostics & Research). What it does: Sells diagnostic tests that measure residual blood cancer cells and immune profiling services for pharmaceutical drug discovery. Sequences adaptive immune receptors to decode individual immune responses for clinical diagnostics and drug discovery. It is worth $4.54B on the market and sold $297.94M over the last year.
- Market cap
- $4.54B
- P/E ratio
- None (reported a loss)
- Annual sales
- $297.94M
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Brief updated
- Nov 18, 2026
Brands and businesses behind ADPT
- clonoSEQ: A diagnostic test that generates revenue by billing insurers for measuring leftover cancer cells in patients.
- immunoSEQ: An immune profiling platform that earns fees by sequencing immune cell receptors for pharmaceutical research clients.
ADPT’s flags, in plain English
Each flag is a number from Adaptive Biotechnologies’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 18, 2026.
Wide Gross Margin
Gross margin of 71.6% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Stupid Cash
Can pay this year's bills 4 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Still Climbing
Sales up 23% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.
Debt Is Driving
Heavy debt, 232% of shareholder equity. The company owes a lot compared with what it earns. Lenders get paid before shareholders, which leaves management fewer options in a weak year.
1 more risk note open with the free trial. Try it free for 7 days.
Questions about ADPT
How big is Adaptive Biotechnologies?
Adaptive Biotechnologies’ market cap is $4.54B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $297.94M: what customers paid the company over the last year, before any costs.
What is ADPT’s P/E ratio?
ADPT has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.
What could go wrong with ADPT?
The company continues to lose money each year and generates negative cash flow from operations. That is one risk on Adaptive Biotechnologies’ card. Its first risk flag is Debt Is Driving, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Adaptive Biotechnologies’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. ADPT’s filings on SEC.gov. The Margin Monkey is research, not advice.
